// App-Quantinova.ai

321 : Pattern of CA19-9 response to neoadjuvant chemotherapy in locally advanced, borderline resectable pancreatic cancer to predict progression.

Researchers

Presenter

  • J Bart Rose

Principal Investigators

  • Alicia M Edwards

  • Adnan Alseidi

  • Thomas R Biehl

  • Bruce S. Lin

  • Vincent J. Picozzi

  • Flavio G. Rocha

  • Scott Helton

Medical Centers

  • Virginia Mason Medical Center, Seattle, WA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Pancreatic cancer

Biomarkers

  • Carbohydrate antigen 19-9

Drug/Treatment

  • Gemcitabine

  • Docetaxel

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved